Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1300 participants.

Also called NCT07866066

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,300 participants (planned count) (from the registry)
Sponsor
  • Amgen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07866066
  • EU CT 2025-523772-22-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07866066. Randomized; no masking; primary purpose treatment. Start 2026-10-16 (actual); primary completion 2028-09-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes
Acronym
MARITIME-T2D-3
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Maridebart cafraglutide
Intervention (Drug)
Semaglutide
Lead sponsor
Amgen (class: industry)

Record details

Record id
cardio:ct-nct07866066
Content hash
5405436d803879aef1a11267fbf14f397cc7b6de9b9db7c3bfb3ca572b738ca7